Annexon Bioscience

2011FOUNDED

PRIVATESTATUS

Series BLATEST DEAL TYPE

$44MLATEST DEAL AMOUNT

6INVESTORS

Description

Developer of therapeutics for neurodegenerative disorders intended to develop disease-modifying therapeutics. The company's therapeutics for neurodegenerative disorders includes a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain, as occurs in Alzheimer's disease and Huntington's disease, as well as in retinal cells, as seen in glaucoma, enabling medical institutes to protect against synapse loss and inflammatory nerve damage in brain and retinal cells.